Similarly, an open-label trial of mavacamten in patients with left ventricular hypertrophy and symptomatic HFpEF (defined as a NYHA functional class II or III, LVEF ≥60% and elevation in NT-proBNP at baseline), has also demonstrated reductions in the same biomarkers of cardiac wall stress and injury.25 Here, NPPB is linked to left ventricular hypertrophy.